Sarepta Therapeutics, Inc. short interest in 2022
In 2022, Sarepta Therapeutics, Inc.'s disclosed short interest ran from 5.20% of shares outstanding on 14 Jan 2022 to 7.79% on 30 Dec 2022, a change of +2.59 percentage points. The year's high was 9.16% on 31 Oct 2022 and its low 5.20% on 14 Jan 2022, averaging 6.82% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.30 days on 15 Dec 2022. Full history: Sarepta Therapeutics, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2022 in figures
- Start of year
- 5.20% (14 Jan 2022)
- End of year
- 7.79% (30 Dec 2022)
- Change
- +2.59 pp
- High
- 9.16% (31 Oct 2022)
- Low
- 5.20% (14 Jan 2022)
- Average
- 6.82%
- Highest days to cover
- 9.30 (15 Dec 2022)
- SEC filings marked
- 5
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 5.20% | 2.95 | results (8-K) |
| 31 Jan 2022 | 6.75% | 3.77 | |
| 15 Feb 2022 | 6.29% | 7.99 | |
| 28 Feb 2022 | 6.16% | 8.81 | |
| 15 Mar 2022 | 6.09% | 6.12 | 10-K filed |
| 31 Mar 2022 | 5.93% | 7.62 | |
| 14 Apr 2022 | 5.62% | 6.99 | |
| 29 Apr 2022 | 5.52% | 7.25 | |
| 13 May 2022 | 5.83% | 5.52 | 10-Q filed |
| 31 May 2022 | 5.72% | 7.06 | |
| 15 Jun 2022 | 5.69% | 8.30 | |
| 30 Jun 2022 | 5.97% | 6.24 | |
| 15 Jul 2022 | 6.13% | 4.79 | |
| 29 Jul 2022 | 5.84% | 5.98 | |
| 15 Aug 2022 | 7.83% | 4.80 | 10-Q filed |
| 31 Aug 2022 | 7.48% | 7.75 | |
| 15 Sep 2022 | 7.79% | 4.58 | |
| 30 Sep 2022 | 8.39% | 7.72 | |
| 14 Oct 2022 | 8.27% | 7.57 | |
| 31 Oct 2022 | 9.16% | 7.70 | |
| 15 Nov 2022 | 8.37% | 6.89 | 10-Q filed |
| 30 Nov 2022 | 7.96% | 7.92 | |
| 15 Dec 2022 | 7.87% | 9.30 | |
| 30 Dec 2022 | 7.79% | 8.58 |
See also: Sarepta Therapeutics, Inc.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.